Veracyte/$VCYT
1D1W1MYTD1Y5YMAX
Capital at risk
About Veracyte
Veracyte Inc is a genomic diagnostics company. The group empowers clinicians with the insights necessary to guide and assure patients at pivotal moments in the race to diagnose and treat cancer. It offers tests for prostate cancer (Decipher Prostate), thyroid cancer (Afirma), breast cancer (Prosigna), and bladder cancer (Decipher Bladder).
- Ticker
- $VCYT
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 755
- Headquarters
- South San Francisco, United States
- Website
- www.veracyte.com
Veracyte Metrics
BasicAdvanced
$3.1B
27.61
$1.39
1.94
-
Price and volume
Market cap
$3.1B
Beta
1.94
52-week high
$60.91
52-week low
$29.46
Average daily volume
1.2M
Financial strength
Current ratio
9.162
Quick ratio
8.598
Long term debt to equity
0.025
Total debt to equity
0.029
Interest coverage (TTM)
89,359.00%
Profitability
EBITDA (TTM)
110.191
Gross margin (TTM)
73.76%
Net profit margin (TTM)
20.37%
Operating margin (TTM)
15.90%
Effective tax rate (TTM)
1.32%
Revenue per employee (TTM)
$740,000
Management effectiveness
Return on assets (TTM)
3.95%
Return on equity (TTM)
8.77%
Valuation
Price to earnings (TTM)
27.612
Price to revenue (TTM)
5.437
Price to book
2.22
Price to tangible book (TTM)
5.75
Price to free cash flow (TTM)
18.406
Free cash flow yield (TTM)
5.43%
Free cash flow per share (TTM)
2.092
Growth
Revenue change (TTM)
17.28%
Earnings per share change (TTM)
313.15%
3-year revenue growth (CAGR)
19.58%
10-year revenue growth (CAGR)
26.25%
3-year earnings per share growth (CAGR)
51.07%
10-year earnings per share growth (CAGR)
0.11%
What the Analysts think about Veracyte
Analyst ratings (Buy, Hold, Sell) for Veracyte stock.
Analyst projections of the future price of Veracyte stock.
Bulls say / Bears say
Core testing momentum is strong: second-quarter testing revenue increased 19% year over year to $145.7 million, led by Decipher Prostate and Afirma, and Veracyte raised its 2026 revenue guidance to $590 million–$596 million. (Veracyte)
Veracyte launched Prosigna as a laboratory-developed test and TrueMRD for muscle-invasive bladder cancer, expanding its addressable cancer-diagnostics portfolio; contemporaneous clinical coverage also reported evidence that its genomic testing may help some breast-cancer patients avoid chemotherapy. (Reuters)
Profitability and liquidity are improving: second-quarter adjusted EBITDA rose 23% year over year to $44.0 million, operating cash flow reached $81.0 million in the first half, and cash plus short-term investments totaled $485.2 million at June 30. (SEC)
Reimbursement and commercial adoption remain execution risks: Veracyte cautions that launching, commercializing and securing reimbursement for its tests may not proceed as expected, particularly for newer products. (Veracyte)
Operating-investment intensity is rising: second-quarter R&D expense increased 81% year over year, while selling and marketing expense rose 12%, creating a risk that launch spending pressures margins if new tests scale slowly. (SEC)
The business is exposed to revenue mix and execution headwinds from the French subsidiary restructuring: biopharmaceutical and other revenue fell sharply, while Prosigna kit costs rose 44% year over year following the transition to contract manufacturing. (SEC)
Data summarised monthly by Lightyear AI. Last updated on 8 Sept 2026.
Veracyte Financial Performance
Revenues and expenses
Veracyte Earnings Performance
Company profitability
Upcoming events
No upcoming events
Veracyte News
AllArticlesVideos
Funds containing Veracyte
AllUSDEURGBP
Fund name | Fund size | $VCYT weighting |
|---|---|---|
iShares Healthcare Innovation$HEAL | $1.4B | 0.34% |
iShares Healthcare Innovation€2B78 | €1.2B | 0.34% |
iShares Healthcare Innovation£DRDR | £1B | 0.34% |
iShares Nasdaq US Biotechnology$BTEC | $1.2B | 0.22% |
iShares Nasdaq US Biotechnology£BTEK | £865M | 0.22% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.